News Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia Michael O'Riordan May 30, 2024
News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Conference News EAS 2019 Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality Michael O'Riordan June 05, 2019
News Conference News EAS 2019 Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients Michael O'Riordan May 30, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Conference News EAS 2018 EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms Yael L. Maxwell May 11, 2018
News Conference News EAS 2017 Diet, Exercise, and Gut Bacteria Play Different, Overlapping Roles in Cardiometabolic Disease Development Yael L. Maxwell May 03, 2017
News Conference News EAS 2017 Perceived Financial Barriers to Healthcare Worsen Cardiovascular Outcomes Even in Countries With Universal Medical Coverage Yael L. Maxwell April 27, 2017
News Conference News EAS 2017 Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both Yael L. Maxwell April 25, 2017
News Conference News EAS 2016 Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease Yael L. Maxwell May 31, 2016